Status:

AVAILABLE

Copper Histidinate Treatment for Menkes Disease

Lead Sponsor:

Sentynl Therapeutics, Inc.

Conditions:

Menkes Disease

Eligibility:

All Genders

Up to 6 years

Brief Summary

This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • The subject must have been treated in protocol 09-CH-0059 or must be a newly diagnosed Menkes disease patient in the US.
  • Parent or legal guardian is willing and able to sign and date an informed consent form.
  • Male or female, aged 0 to \<6 years of age.
  • Diagnosis of Menkes disease: A confirmed gene mutation in ATP7A is not required; however, the test must be at least pending prior to initiating therapy. For those patients whose molecular ATP7A gene mutation confirmation is pending, they should have serum copper \<75 mcg/dL. If the mutation is subsequently not confirmed, the patient should discontinue treatment.
  • Ability to adhere to the prescribed subcutaneous copper histidinate injection regimen.
  • Willingness to adhere to all recommended visits and procedures.
  • Resident of the US.
  • Exclusion Criteria
  • Diagnosis of Wilson disease.
  • Any disease or condition that, in the opinion of the Investigator, has a high probability of precluding the subject from completing the study or where the subject cannot or will not appropriately comply with study requirements.
  • Receipt of concomitant medication or device not approved for any use (i.e. experimental) by FDA within 30 days prior to screening for this study, except for participation in protocol 09-CH-0059.
  • Patient/caregiver cannot or will not appropriately comply with protocol recommendations (e.g., site visits, renal monitoring).
  • Currently receiving any concomitant copper-containing medications.

Exclusion

    Key Trial Info

    Start Date :

    Trial Type :

    EXPANDED_ACCESS

    End Date :

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT04074512

    Last Update

    November 12 2025

    Active Locations (20)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (20 locations)

    1

    Phoenix Children's Hospital

    Phoenix, Arizona, United States, 85016

    2

    University of California Davis Medical Center

    Sacramento, California, United States, 95817

    3

    Rady Children's Hospital

    San Diego, California, United States, 92123

    4

    Children's Hospital Colorado

    Aurora, Colorado, United States, 80045